About - Practical Recommendations in Immuno and Molecular Oncology (PRIMO)

About

The 2025 Annual
PRIMO Meeting

The PRIMO meeting Co-Chairs, Steering Committee, and Education Committee have curated an agenda to meet the educational needs of all attendees and will focus on the following key areas:
  • Practical considerations of applying biomarkers and targeted therapy
  • Integration of immunotherapy, with a focus on novel management approaches
  • Patient selection, as well as timing and sequencing of therapy
  • Dealing with important trends, such as big data and defining value in cancer care
Wednesday, February 5, 2025
12:00 PM – 8:00 PM
Registration
6:30 PM – 8:00 PM
Welcome reception at ‘Alohilani Resort Waikiki Beach
Join us in honoring the 2025 Women in Oncology Award winner
Thursday, February 6, 2025
6:30 AM – 3:00 PM
Exhibits & VIP Lounge Open
7:00 AM – 7:05 AM
Meeting Welcome
Sanjiv S. Agarwala, MD, FASCO
7:05 AM – 7:10 AM
Program Overview
Hope S. Rugo, MD, FASCO
Julie M. Vose, MD, MBA
Hematologic Malignancies
Session Chair: Julie M. Vose, MD, MBA
7:10 AM – 7:30 AM
Sequencing of Therapies for Multiple Myeloma
Tom Martin, MD
7:30 AM – 7:50 AM
Treatment of Patients Progressing after BTKi and BCL2i
Nitin Jain, MD
7:50 AM – 8:10 AM
Update on Therapies for MDS and AML
Eunice S. Wang, MD
8:10 AM – 8:30 AM
Novel Therapies for Aggressive Non-Hodgkin Lymphomas
Kami J. Maddocks, MD
8:30 AM – 8:50 AM
Q/A Panel Discussion
Julie M. Vose, MD, MBA
Tom Martin, MD
Nitin Jain, MD
Eunice S. Wang, MD
Kami J. Maddocks, MD
Product Theater
9:00 AM – 9:45 AM
Product Theater Breakfast Showcase (Non-CE)
9:45 AM – 10:00 AM
Energize and Visit Exhibits | VIP Lounge Open

10:00 AM – 10:15 AM
Women in Oncology Keynote Presentation
Multidisciplinary Approach to Cancer
Session Co-Chairs: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE and Shane Y. Morita, MD, MS, PhD, FACS
10:15 AM – 10:40 AM
The Neoadjuvant Revolution
10-minute presentation and 15 minute multi-disciplinary discussion
Speaker: Merrick I. Ross, MD

Discussants:
Daniel Ahn, DO, MS
Chandler H. Park, MD, MSc, FACP
Jorge J. Nieva, MD
10:40 AM – 11:00 AM
Will Biosimilars Reduce Financial Toxicity of Cancer Therapy
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE
11:00 AM – 11:05 AM
Q/A
11:05 AM – 11:35 AM
Panel: Navigating the Landscape of Oncology Care in the State of Hawaii
Shane Y. Morita, MD, MBA, PhD, FACS
Michael E. Carney, MD, FACOG
Kristen Chun, RN, BSN, MBA/HCM
Thomas Samuel Shomaker, MD, JD
Naoto T. Ueno, MD, PhD
Product Theater
11:45 AM – 12:30 PM
Product Theater Lunch Showcase (Non-CE)
12:30 PM – 12:45 PM
Desserts and Visit Exhibits | VIP Lounge Open
Gastrointestinal Malignancies
Session Chair: Daniel Ahn, DO, MS
12:45 PM – 1:05 PM
Hepatocellar Carcinoma: Are We Finally Making Progress?
Daniel Ahn, DO, MS
1:05 PM – 1:25 PM
Esophageal Carcinoma – Finally Something Practice Changing
Midhun Malla, MD
1:25 PM – 1:45 PM
Q/A Panel Discussion
Daniel Ahn, DO, MS
Midhun Malla, MD, MS
Evening Reception*
5:30 PM – 7:00 PM
Sunset Mingle Networking Event (*by invite only)
Friday, February 7, 2025
6:30 AM – 3:00 PM
Exhibits & VIP Lounge Open
7:00 AM – 7:05 AM
Welcome and Program Overview
Sanjiv S. Agarwala, MD, FASCO
The Changing Face of Cancer Therapeutics
Session Chair: Sanjiv S. Agarwala, MD, FASCO
7:05 AM – 7:20 AM
Artificial Intelligence in Cancer Therapeutics: Fact or Fiction?
Sanjay Juneja, MD
7:20 AM – 7:25 AM
Q/A
7:25 AM – 7:40 AM
Telehealth – Is It the Future of Palliative and Supportive Care?
Cedric "Jamie" Rutland MD, FCCP
7:40 AM – 7:45 AM
Q/A
Product Theater
8:00 AM – 8:45 AM
Product Theater Breakfast Showcase (Non-CE)
8:45 AM – 9:15 AM
Energize and Visit Exhibits | VIP Lounge Open
Lung & Aerodigestive Cancer
Session Chair: Luis E. Raez, MD, FACP, FASCO
9:15 AM – 9:30 AM
New Developments in Small Cell Lung Cancer
Jyoti D. Patel, MD, FASCO
9:30 AM – 9:45 AM
Targeted Therapy and Resistance, New Agents are Coming
Misako Nagasaka, MD
9:45 AM – 10:00 AM
Antibody Drug Conjugates in Lung Cancer
Jorge J. Nieva, MD
10:00 AM – 10:15 AM
Perioperative Immunotherapy in NSCLC
Luis E. Raez, MD, FACP, FASCO
10:15 AM – 10:25 AM
Q/A Panel Discussion
Luis E. Raez, MD, FACP, FASCO
Jyoti D. Patel, BA, MD
Tejas Patil, MD
Jorge J. Nieva, MD
10:25 AM – 11:10 AM
Lung Cancer Tumor Board with CEN
Moderator:
Luis E. Raez, MD, FACP, FASCO
1 Case Each:
Jyoti D. Patel, MD, FASCO
Misako Nagasaka, MD
Jorge J. Nieva, MD
+ Participant from Hawaii
Product Theater
11:15 AM – 12:00 PM
Product Theater Lunch Showcase (Non-CE)
12:00 PM – 12:15 PM
Desserts and Visit Exhibits | VIP Lounge Open
Genitourinary
Session Chair: Ulka Vaishampayan, MD
12:15 PM – 12:35 PM
RCC in 2025: What’s New for the Practicing Oncologist?
Ulka Vaishampayan, MD
12:35 PM – 12:55 PM
Prostate and Bladder Cancers: What Have we Learned Over the Past Year?
Chandler H. Park, MD, MSc, FACP
12:55 PM – 1:30 PM
Discussion and GU Tumor Board with CEN
Ulka Vaishampayan, MD
Chandler H. Park, MD, MSc, FACP
+ Participant from Hawaii
Saturday, February 8, 2025
6:30 AM – 11:00 AM
Exhibits open
7:00 AM – 7:05 AM
Welcome and Program Overview
Hope S. Rugo, MD, FASCO
Reproductive Cancers in Women
Session Chair: Don Dizon, MD, FACP, FASCO
7:05 AM – 7:25 AM
Incorporating Immunotherapy in the Management of Cervical Cancer
Susana Campos, MD
7:25 AM – 7:45 AM
Molecular Classification in Endometrial Cancer: A Real-World Approach to Staging and Treatment
Alexander B. Olawaiye, MD, FRCOG, FACOG, FACS
7:45 AM – 8:05 AM
Immunotherapy in Ovarian Cancer: Is There a Role, and for Whom?
Don Dizon, MD, FACP, FASCO
8:05 AM – 8:20 AM
Q/A + Rapid Gynecologic Oncology Tumor Board
Susana Campos, MD, MPH
Alexander B. Olawaiye, MD, FRCOG, FACOG, FACS
Don Dizon, MD, FACP, FASCO
Breast Tumor Board
Moderator: Hope S. Rugo, MD, FASCO
8:20 AM – 9:10 AM
Join Forces with our Breast KOLs and Participate in an Active Discussion on the Most Interesting Breast Cases - 2 Cases
Case Presenter: Jami Fukui, MD

Board: Breast Cancer Faculty
Vincente Valero, MD, FACP
Mark Pegram, MD
Joyce O’Shaughnessy, MD
Hope Rugo, MD, FASCO
Product Theater
9:15 AM – 10:00 AM
Product Theater Breakfast Showcase (Non-CE)
10:00 AM – 10:15 AM
Energize and Visit Exhibits
Breast Cancer
Session Chair: Hope S. Rugo, MD, FASCO
10:15 AM – 10:35 AM
Major Endocrine and Targeted Therapy Advances In the Treatment of HR+/HER2- Breast Cancer
Vincente Valero, MD, FACP
10:35 AM – 10:55 AM
Advances in the Treatment of HER2+ Breast Cancer
Mark Pegram, MD
10:55 AM – 11:15 AM
New Directions In Chemotherapy and Immunotherapy for HR+ Breast Cancer
Joyce O’Shaughnessy, MD
11:15 AM – 11:35 AM
Immunotherapy and Optimal Chemotherapy for Early Stage TNBC: When and in Whom?
Hope Rugo, MD, FASCO
11:35 AM – 11:45 AM
Q/A Panel Discussion
Hope S. Rugo, MD, FASCO
Vincente Valero, MD, FACP
Mark Pegram, MD
Joyce O’Shaughnessy, MD
11:45 AM – 11:50 AM
Closing Remarks
Sanjiv S. Agarwala, MD, FASCO
Hope S. Rugo, MD, FASCO
Julie Vose, MD, MBA

We acknowledge commercial support from Taiho Oncology, Exelixis, Pfizer, AstraZeneca, and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Registration

Registration Type Early
Ends Augustus 31, 2024		 Regular
Sep-Dec 31, 2024		 Late
Jan 1-Feb 5, 2025		 One-day
pass
Physician
$445.00
$545.00
$645.00
$250.00
Allied Health
$345.00
$445.00
$545.00
$200.00
Resident/Fellow
$295.00
$395.00
$495.00
$175.00
Industry: Professional of Exhibiting Company
$1,500.00
$2,000.00
$2,500.00
N/A
Industry: Non-exhibiting Company
$5,000.00
$5,000.00
$5,000.00
$5,000.00
MauiStriong-Banner

Join your colleagues and explore key developments in cancer care over the past 12 months as well as the anticipated advances that you and your patients will likely see in the upcoming year.

Target Audience

This activity has been designed to meet the educational needs of Academic and Community Practitioners, from all oncology specialties, to include physicians, nurses and nurses practitioners, physician associates,  pharmacists and other healthcare professionals treating all disease sites involved in the care or patients with cancer.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe the rationale for mechanisms of action for molecular targeted and immunologic therapies used to treat cancer today;
  • Summarize recent advances in targeted and immunologic treatment of hematologic malignancies and solid tumors;
  • Identify patients who are appropriate candidates for targeted and immunologic therapies;
  • Implement strategies from a healthcare team approach to reduce treatment-related toxicities, and optimize patient outcomes;
  • Discuss promising targeted and immunologic approaches being tested in late-stage clinical trials.

The Practical Recommendations in Immuno and Molecular Oncology Meeting is a unique opportunity to receive CE credits while staying ahead of the latest advances in immuno and molecular oncology.

The Annual PRIMO Meeting is designed to summarize key developments in cancer care over the past 12 months and features anticipated advances that you and your patients will likely see in the upcoming year.

Accredited by:

MEC Logo

Accreditation and Credit Statements

JA Commendation Mark

In support of improving patient care, The Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE Credit Logo

This activity was planned by and for the healthcare team, and learners will receive 12.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician

The Medical Educator Consortium designates this live activity for a maximum of 12.00 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME MOC Logo

“Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.00 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.”

Learner participation will be shared through the ACCME’s Program and Activity Reporting System (PARS)

Nursing

The Medical Educator Consortium designates this activity for 12.00 contact hours.

Pharmacist

This Application-based activity has been approved for 12.00 contact hours (1.20 CEU) by The Medical Educator Consortium. The Universal Activity Number for this program is  JA4008179-0000-25-001-L01-P. Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.

Physician Associate

AAPA Cat1 CME logo

The Medical Educator Consortium has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 12.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

DISCLOSURE POLICY

The Medical Educator Consortium (MEC) adheres to the Joint Accreditation Criteria and the ACCME Standards for Integrity and Independence in Accredited Continuing Education. As a Joint Accreditation (JA) provider, decisions in the planning process of this conference were made free of the control of ineligible companies. All persons that will be in a position to control the content of the CE Activity are required to disclose all relevant financial relationships, regardless of the amount, that they have had in the past 24 months with ineligible companies. MEC has implemented a mechanism to identify, mitigate and disclose relevant financial relationships prior to the education activity being delivered to learners. A Disclosure Index document outlining this information will be made available to participants prior to the educational activity. The source of all commercial support from ineligible companies will also be disclosed to learners prior to the beginning of the educational activity. CE activities must be balanced, independent of commercial bias, and designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence within the medical profession.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contradictions, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contradictions and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

PRIMO 2020
at a Glance

26 Conference Sponsors